Plain Language Summary {#Sec1}
======================

The high blood glucose levels that characterise type 2 diabetes mellitus (T2DM) are treated using antihyperglycaemic drugs. Patients' responses to antihyperglycaemic drugs, which are usually evaluated by measuring glycated haemoglobin (HbA~1c~), are affected by several factors, including the patient's baseline HbA~1c~ level. Previous investigations of this topic have involved dividing the baseline HbA~1c~ values of the patient population into a number of categories. However, this loses potentially valuable information. In this analysis, we treated baseline HbA~1c~ as a continuous variable. Our analysis used data from three large clinical trials to investigate changes in HbA~1c~ in patients with T2DM who received one of four different antihyperglycaemic agents: dulaglutide (0.75 or 1.5 mg once weekly), sitagliptin (100 mg once daily), liraglutide (1.8 mg once daily), or exenatide (10 μg twice daily). The patients had a range of baseline HbA~1c~ values.

In all treatment groups, improvements in HbA~1c~ occurred across the entire baseline HbA~1c~ range and patients with higher baseline HbA~1c~ values showed greater reductions. The mean HbA~1c~ reduction was similar in patients treated with dulaglutide 1.5 mg and those receiving liraglutide 1.8 mg across the range of baseline HbA~1c~ values. However, patients receiving dulaglutide 1.5 mg had greater reductions than patients receiving exenatide or sitagliptin. As baseline HbA~1c~ increased, patients receiving dulaglutide had progressively greater HbA~1c~ reductions compared with those receiving sitagliptin. These results suggest that dulaglutide is an appropriate therapy for patients with T2DM across a wide range of baseline HbA~1c~ values, including those with poor blood glucose control.

Introduction {#Sec2}
============

For patients with type 2 diabetes mellitus (T2DM), treatment with most antihyperglycaemic agents---including incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors---is associated with an improvement in glycated haemoglobin (HbA~1c~) levels \[[@CR1]--[@CR4]\]. Baseline HbA~1c~ is a predictor of HbA~1c~ change in patients responding to treatment, with greater reductions in HbA~1c~ levels occurring in patients with higher baseline values \[[@CR5]--[@CR11]\]. Of clinical interest is a meta-analysis involving DPP-4 inhibitors, which indicated that the baseline HbA~1c~ level was the strongest predictive factor for change in HbA~1c~ \[[@CR8]\]. Similar results have been found for the GLP-1 RA dulaglutide \[[@CR11]\].

Dulaglutide has demonstrated significant improvements in HbA~1c~, and fasting and postprandial blood glucose levels in patients with T2DM, and is associated with a substantial percentage of patients achieving HbA~1c~ \< 7% (53.0 mmol/mol) \[[@CR12]--[@CR19]\]. These effects are durable up to 104 weeks \[[@CR16], [@CR20]\]. This agent also demonstrates a potential for weight loss and has a safety profile similar to that of other agents in the GLP-1 RA class \[[@CR21]\].

A post hoc analysis of data from the AWARD trials that used gradient-boosting analysis and multivariable regression to examine baseline factors associated with glycaemic response in dulaglutide-treated patients with T2DM \[[@CR11]\] found that higher baseline HbA~1c~ was the major factor associated with a greater reduction in HbA~1c~ (a 1% \[11 mmol/mol\] increase in baseline HbA~1c~ was associated with a decrease in HbA~1c~ of 0.60% \[6.54 mmol/mol; *P* \< 0.0001\]).

When comparing antihyperglycaemic agents with each other, it is often of interest to understand whether patients experience different responses to each treatment according to baseline or disease characteristics of interest. In the case of a continuous variable, such as baseline HbA~1c~, this is typically done by dividing the population into subgroups on the basis of HbA~1c~ level before applying the statistical model \[[@CR22]--[@CR25]\]. For example, both Bain et al. \[[@CR24]\] and Gallwitz et al. \[[@CR25]\] divided their respective GLP-1 RA-treated populations into two subgroups (baseline HbA~1c~ \< 8.5% and ≥ 8.5%). Baseline HbA~1c~ was thus treated as a categorical variable. Although informative, this type of analysis fails to utilise all the information provided by a continuous variable \[[@CR26]\]. It is also associated with reduced statistical power, increased risk of a false positive result, underestimation of the extent to which the outcome varies among groups, and potential concealment of a non-linear relationship between variable and outcome \[[@CR26]\]. In addition, this approach can result in the performance of multiple analyses if more than one set of cutoffs is used to generate the categories (e.g. \< 8.5% vs ≥ 8.5% followed by \< 7.5% vs ≥ 7.5%) and, as a consequence, it may generate conflicting results. In order to avoid these problems, in the current analysis we have treated baseline HbA~1c~ as a continuous variable---an approach that allows us to fully explore the relationship between baseline HbA~1c~ and antihyperglycaemic endpoints both within and between treatment groups. This analysis---which represents an alternative to the more typical (categorical) analysis---should provide a deeper understanding of changes in antihyperglycaemic measures associated with individual agents in patients with different baseline HbA~1c~ values, and of the relative changes associated with different agents in patients at each level of baseline glycaemia. To our knowledge, this type of analysis has not been previously performed on HbA~1c~ data from patients with T2DM who are receiving incretin therapies.

In the present post hoc analysis, we used data from three phase III randomised controlled AWARD trials to investigate the consistency of glycaemic response across a continuous range of baseline HbA~1c~ values, in patients treated with once-weekly dulaglutide 1.5 mg and 0.75 mg versus other incretin-based therapies: the DPP-4 inhibitor, once-daily sitagliptin 100 mg (AWARD-5 \[[@CR13]\]), and the GLP-1 RAs, once daily liraglutide 1.8 mg (AWARD-6 \[[@CR14]\]) and twice-daily exenatide 10 μg (AWARD-1 \[[@CR15]\]). These three AWARD trials were selected for this analysis because they involved an incretin-based comparator and enrolled patients with T2DM with a wide and continuous range of baseline HbA~1c~ values. Each of these trials demonstrated that dulaglutide is at least as efficacious as these other incretin-based therapies and has an acceptable tolerability and safety profile.

Methods {#Sec3}
=======

This exploratory post hoc analysis included data from all adult patients enrolled in the intent-to-treat (ITT) populations who received active treatment (dulaglutide or another incretin-based therapy) in AWARD-5, AWARD-6 and AWARD-1. AWARD-5 and AWARD-1 patients randomised to receive placebo were not included in the analysis. The design and results of these trials have been previously published \[[@CR13]--[@CR15]\]. Each of these original studies was conducted in accordance with the Declaration of Helsinki guidelines on good clinical practice. In all cases the protocol was approved by local institutional review boards, and all patients provided written informed consent before participation in the trial \[[@CR13]--[@CR15]\]. The full list of institutional review boards that approved the three studies can be found in the Supplementary Material (Table S1). A summary of each of these trials is provided below.

In AWARD-5 \[[@CR13]\], 921 patients with T2DM on metformin (≥ 1500 mg/day) were randomised to receive concomitant therapy with once-weekly dulaglutide 1.5 mg or 0.75 mg, or once-daily sitagliptin 100 mg. Patients were eligible for inclusion if, at screening, their HbA~1c~ was \> 8% and ≤ 9.5% (\> 63.9 and 80.3 mmol/mol), if treated with diet and exercise, or ≥ 7.0% and ≤ 9.5% (≥ 53.0 and ≤ 80.3 mmol/mol) if receiving oral antihyperglycaemic medication. Eligible patients then entered a lead-in period that lasted up to 11 weeks. During the lead-in period, patients received metformin monotherapy (minimum dose ≥ 1500 mg/day) for ≥ 6 weeks prior to randomisation; all other oral antihyperglycaemic medications were discontinued.

In AWARD-6 \[[@CR14]\], 599 patients with T2DM on metformin (≥ 1500 mg/day) were randomised to receive concomitant therapy with once-weekly dulaglutide 1.5 mg or once-daily liraglutide 1.8 mg. Patients treated with antihyperglycaemic drugs other than metformin were excluded. The inclusion criteria included an HbA~1c~ level ≥ 7.0% and ≤ 10.0% (≥ 53.0 and ≤ 85.8 mmol/mol) at screening. This study did not include a lead-in period.

In AWARD-1 \[[@CR15]\], 835 patients with T2DM on maximally tolerated doses of metformin (1500--3000 mg/day) and pioglitazone (30--45 mg/day) were randomised to receive concomitant therapy with once-weekly dulaglutide 1.5 mg or 0.75 mg, or exenatide 10 μg twice daily. At screening, patients were eligible for inclusion if their HbA~1c~ was ≥ 7.0% and ≤ 11.0% (≥ 53.0 and ≤ 96.7 mmol/mol), if on oral antihyperglycaemic medication monotherapy, or ≥ 7.0% and ≤ 10.0% (≥ 53.0 and ≤ 85.8 mmol/mol) if on combination oral antihyperglycaemic medication. After a lead-in period that lasted up to 12 weeks, patients were eligible for randomisation if their HbA~1c~ was \> 6.5% (\> 47.5 mmol/mol). Previous oral antihyperglycaemic medications other than metformin and pioglitazone were discontinued during the lead-in period.

In the current post hoc analysis, changes in HbA~1c~ were evaluated at week 26 for each of the trials (AWARD-5, AWARD-6 and AWARD-1). Week-52 data are available for one study only (AWARD-5) and are mentioned briefly. Data were analysed by study using last observation carried forward (LOCF) analysis of covariance (ANCOVA), starting with the predefined statistical models from the respective study protocols, which assumed a linear association between baseline HbA~1c~ and change in HbA~1c~.

Backward selection methods were applied to assess whether the respective predefined models were appropriately capturing this linear association or needed to be adapted. In order to produce meaningful and interpretable estimates and *P* values for the factor treatment, the factor for baseline HbA~1c~ and the treatment-by-baseline HbA~1c~ factor were centred around a baseline HbA~1c~ of 8.0% (63.9 mmol/mol). Consistency of potential treatment effect across the range of baseline HbA~1c~ values was investigated via the corresponding treatment-by-baseline HbA~1c~ interaction term, with *P* \< 0.1 interpreted as a potential differential treatment effect. Sensitivity analyses were performed as appropriate, using only data from patients treated with active therapy in the ITT population of each study who met the HbA~1c~ inclusion criteria.

Baseline characteristics data are presented for the active treatment arms (dulaglutide and incretin-based comparators) of the ITT population of each study; full baseline characteristics for each of the respective studies have been previously published \[[@CR13]--[@CR15]\].

Results {#Sec4}
=======

Patient Characteristics {#Sec5}
-----------------------

Baseline characteristics for the patients in the ITT population who were enrolled in the three phase III studies and received active treatment are shown in Table [1](#Tab1){ref-type="table"}. Patients in AWARD-6 and AWARD-1 tended to have a higher weight and body mass index than those in AWARD-5, and the disease duration was longer in AWARD-1 than in AWARD-5 and AWARD-6. All other baseline characteristics were similar across the studies \[[@CR13]--[@CR15]\]. The mean baseline HbA~1c~ was generally similar (mean value, 8.1% \[65.0 mmol/mol\] in all treatment groups across the studies), although the range of baseline HbA~1c~ values (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and S2; Fig. [1](#Fig1){ref-type="fig"}) differed among studies as a result of differences in study inclusion/exclusion criteria (see "[Methods](#Sec3){ref-type="sec"}" section).Table 1Baseline characteristics of patients receiving active treatmentCharacteristicAWARD-5AWARD-6AWARD-1DU 1.5DU 0.75SITADU 1.5LIRA 1.8DU 1.5DU 0.75EXE(*n* = 304)(*n* = 302)(*n* = 315)(*n* = 299)(*n* = 300)(*n* = 279)(*n* = 280)(*n* = 276)Female, *n* (%)158 (52)168 (56)164 (52)161 (54)151 (50)116 (42)112 (40)120 (44)Age (years)54 (10)54 (10)54 (10)57(9)57 (10)56 (10)56 (9)55 (10)Weight (kg)87 (17)86 (18)86 (17)94 (18)94 (19)96 (20)96 (21)97 (19)BMI (kg/m^2^)31 (5)31 (4)31 (4)34 (5)34 (5)33 (5)33 (6)34 (5)HbA~1c~ (%) \[range^a^\]8.1 (1.1) \[5.1--13.2\]8.2 (1.1) \[6.3--13.9\]8.1 (1.1) \[6.0--12.8\]8.1 (0.8) \[6.5--10.5\]8.1 (0.8) \[6.4--10.5\]8.1 (1.3) \[6.3--13.8\]8.1 (1.2) \[6.2--13.0\]8.1 (1.3) \[6.3--13.5\]HbA~1c~ (mmol/mol) \[range^a^\]65 (12) \[32--121\]66 (12) \[45--128\]65 (12) \[43--116\]65 (9) \[48--91\]65 (9) \[46--91\]65 (14) \[45--127\]65 (13) \[44--119\]65 (14) \[45--124\]Diabetes duration (years)7 (6)7 (5)7 (5)7 (5)7 (5)9 (6)9 (5)9 (6)The table shows data from all patients in the intention-to-treat populations of AWARD-5, AWARD-6 and AWARD-1. Values shown are for mean (SD) unless otherwise noted*BMI* body mass index, *DU* dulaglutide (dose in mg), *EXE* exenatide twice daily, *LIRA* liraglutide (dose in mg), *SITA* sitagliptin^a^Observed range at baseline Table 2Least squares mean (95% CI) reductions from baseline in HbA~1c~ (%) across the range of baseline HbA~1c~ in AWARD-5, AWARD-6 and AWARD-1 at week 26TreatmentBaseline HbA~1c~ (%)6.57.07.58.08.5AWARD-5^a^ DU 0.75-- − 0.67 (− 0.82, − 0.52) − 0.81 (− 0.93, − 0.69) − 0.95 (− 1.06, − 0.85) − 1.10 (− 1.21, − 0.99) DU 1.5-- − 0.71 (− 0.86, − 0.56) − 0.93 (− 1.05, − 0.81) − 1.15 (− 1.26, − 1.05) − 1.37 (− 1.48, − 1.26) SITA-- − 0.36 (− 0.50, − 0.22) − 0.46 (− 0.57, − 0.34) − 0.56 (− 0.66, − 0.46) − 0.66 (− 0.77, − 0.55)AWARD-6^b^ DU 1.5-- − 0.95 (− 1.10, − 0.80) − 1.20 (− 1.31, − 1.08) − 1.44 (− 1.54, − 1.35) − 1.69 (− 1.80, − 1.58) LIRA 1.8-- − 0.84 (− 1.00, − 0.69) − 1.11 (− 1.23, − 0.99) − 1.38 (− 1.48, − 1.28) − 1.65 (− 1.76, − 1.54)AWARD-1^a^ DU 0.75 − 0.55 (− 0.71, − 0.39) − 0.80 (− 0.93, − 0.66) − 1.04 (− 1.16, − 0.92) − 1.29 (− 1.41, − 1.17) − 1.54 (− 1.66, − 1.41) DU 1.5 − 0.66 (− 0.82, − 0.49) − 0.94 (− 1.08, − 0.80) − 1.22 (− 1.34, − 1.10) − 1.50 (− 1.62, − 1.38) − 1.78 (− 1.90, − 1.66) EXE − 0.17 (− 0.33, − 0.01) − 0.44 (− 0.58, − 0.30) − 0.71 (− 0.83, − 0.59) − 0.98 (− 1.10, − 0.86) − 1.25 (− 1.37, − 1.13)TreatmentBaseline HbA~1c~ (%)9.09.510.010.511.0AWARD-5^a^ DU 0.75 − 1.24 (− 1.37, − 1.11) − 1.38 (− 1.54, − 1.23) −  −  −  DU 1.5 − 1.59 (− 1.72, − 1.46) − 1.81 (− 1.97, − 1.65) −  −  −  SITA − 0.76 (− 0.89, − 0.63) − 0.86 (− 1.02, − 0.70) −  −  − AWARD-6^b^ DU 1.5 − 1.94 (− 2.09, − 1.79) − 2.18 (− 2.38, − 1.99) − 2.43 (− 2.68, − 2.19) −  −  LIRA 1.8 − 1.92 (− 2.06, − 1.77) − 2.18 (− 2.38, − 1.99) − 2.45 (− 2.70, − 2.21) −  − AWARD-1^a^ DU 0.75 − 1.78 (− 1.93, − 1.64) − 2.03 (− 2.20, − 1.86) − 2.28 (− 2.48, − 2.08) − 2.53 (− 2.76, − 2.30) − 2.77 (− 3.04, − 2.51) DU 1.5 − 2.06 − 2.20, − 1.93) − 2.34 (− 2.50, − 2.19) − 2.63 (− 2.81, − 2.44) − 2.91 (− 3.12, − 2.70) − 3.19 (− 3.43, − 2.95) EXE − 1.52 (− 1.66, − 1.39) − 1.79 (− 1.95, − 1.63) − 2.06 (− 2.25, − 1.88) − 2.33 (− 2.55, − 2.12) − 2.61 (− 2.85, − 2.36)The table shows data from patients receiving active treatment in the intention-to-treat populations of AWARD-5, AWARD-6 and AWARD-1 whose baseline HbA~1c~ met the inclusion criteria for their respective study*ANCOVA* analysis of covariance, *CI* confidence interval, *DU* dulaglutide (dose in mg), *EXE* exenatide twice daily, *LIRA* liraglutide (dose in mg), *LOCF* last observation carried forward, *SITA* sitagliptin^a^LOCF ANCOVA model: change in HbA~1c~ = treatment + country + baseline HbA~1c~ + treatment × baseline HbA~1c~^b^LOCF ANCOVA model: change in HbA~1c~ = treatment + pooled country + baseline HbA~1c~ + treatment × baseline HbA~1c~ Fig. 1Change in HbA~1c~ by baseline HbA~1c~ and treatment group estimated using LOCF ANCOVA models (for each study, data are presented only for baseline HbA~1c~ values that correspond to the study inclusion criteria). **a** AWARD-5, 26 weeks. LOCF ANCOVA model: treatment + country + baseline HbA~1c~ + treatment × baseline HbA~1c~, interaction *P* value = 0.001. **b** AWARD-6, 26 weeks (primary endpoint). LOCF ANCOVA model: treatment + pooled country + baseline HbA~1c~ + treatment × baseline HbA~1c~; interaction *P* value = 0.605. **c** AWARD-1, 26 weeks (primary endpoint). LOCF ANCOVA model: treatment + country + baseline HbA~1c~ + treatment × baseline HbA~1c~; interaction *P* value = 0.443. ANCOVA analysis of covariance, BID twice daily, CI confidence interval, DU dulaglutide, EXE exenatide, LIRA liraglutide, LOCF last observation carried forward, SITA sitagliptin

**HbA**~**1c**~**Changes** {#Sec6}
--------------------------

Improvements in HbA~1c~ at 26 weeks occurred in all treatment groups across the entire baseline HbA~1c~ range in all studies (Fig. [1](#Fig1){ref-type="fig"}; Tables [2](#Tab2){ref-type="table"} and S1).

Table S3 shows details of the backward selection process and the variables excluded from each ANCOVA model. The association between baseline HbA~1c~ and change in HbA~1c~ was best described by a linear relationship in all studies, with greater reductions in HbA~1c~ occurring in patients with higher HbA~1c~ levels at baseline (Table S3; Fig. [1](#Fig1){ref-type="fig"}). Therefore, the predefined models did not need to be adapted. At week 26, dulaglutide 1.5 mg was associated with mean reductions of \< 1% (\< 10.9 mmol/mol) in patients with good control (baseline HbA~1c~ levels of ≤ 7% \[53.0 mmol/mol\]) in each of the AWARD-5, AWARD-6 and AWARD-1 studies, and with greater mean reductions (1.8--3.2% \[19.7--35.0 mmol/mol\]) in those with poorer control (HbA~1c~ ≥ 9.5% \[80.3 mmol/mol\]). This pattern was also apparent in patients treated with dulaglutide 0.75 mg (AWARD-5 and AWARD-1), although the magnitude of the reduction in HbA~1c~ was slightly smaller at the lower dose (Fig. [1](#Fig1){ref-type="fig"}a, c).

The overall magnitude of the mean reduction in HbA~1c~ at 26 weeks across the continuum of baseline HbA~1c~ values was greater in patients receiving dulaglutide 1.5 mg than in those receiving sitagliptin (AWARD-5; Fig. [1](#Fig1){ref-type="fig"}a) or exenatide twice daily (AWARD-1; Fig. [1](#Fig1){ref-type="fig"}c) and was similar to patients receiving liraglutide 1.8 mg (AWARD-6; Fig. [1](#Fig1){ref-type="fig"}b). These findings are in line with the results of the primary analyses \[[@CR13]--[@CR15]\].

Treatment-by-baseline HbA~1c~ interaction terms for AWARD-6 (interaction *P*value = 0.605; Fig. [1](#Fig1){ref-type="fig"}b) and AWARD-1 (interaction *P* value = 0.443; Fig. [1](#Fig1){ref-type="fig"}c) indicated no differences in the relative change in HbA~1c~ in patients treated with dulaglutide versus those treated with sitagliptin or exenatide twice daily across the whole range of baseline HbA~1c~. This is also illustrated by the similar slopes of the lines describing the relationship between HbA~1c~ baseline and change from baseline. For AWARD-1, a sensitivity analysis on the ITT population using HbA~1c~ values within the inclusion criteria only (7.0--11.0% \[53--97 mmol/mol\]) confirmed this outcome.

In contrast, in AWARD-5, the treatment-by-baseline HbA~1c~ interaction *P* value was significant (*P* = 0.001; Fig. [1](#Fig1){ref-type="fig"}a). This was mainly driven by the progressively greater HbA~1c~ reduction that occurred in patients treated with dulaglutide 1.5 mg compared with sitagliptin as baseline HbA~1c~ increased (estimated treatment group differences in HbA~1c~ reduction \[dulaglutide minus comparator\] of − 0.35% \[− 3.83 mmol/mol\] and − 0.95% \[− 10.38 mmol/mol\] at baseline HbA~1c~ values of 7.0% \[53.0 mmol/mol\] and 9.5% \[80.3 mmol/mol\], respectively; pairwise interaction *P* value = 0.0003). The estimated difference between the change in HbA~1c~ in the dulaglutide 0.75 mg and sitagliptin treatment groups also increased as baseline HbA~1c~ increased, but to a lesser extent (baseline HbA~1c~ = 7.0% \[53.0 mmol/mol\], − 0.31% \[− 3.39 mmol/mol\]; 9.5% \[80.3 mmol/mol\], − 0.52% \[− 5.68 mmol/mol\]; pairwise interaction *P* value = 0.1778). These results were also observed in the 52-week analysis (primary endpoint; interaction *P* value \< 0.001) \[[@CR27]\]. At this time point, the estimated treatment group differences for dulaglutide compared to sitagliptin were greater than at 26 weeks, and the pairwise interaction *P* values were significant for both dulaglutide 1.5 mg (*P* \< 0.001; baseline HbA~1c~ = 7.0% \[53.0 mmol/mol\], estimated treatment group difference =  − 0.36% \[− 3.94 mmol/mol\], 9.5% \[80.3 mmol/mol\], − 1.15% \[− 12.57 mmol/mol\]) and 0.75 mg (*P* = 0.026; baseline HbA~1c~ = 7.0% \[53.0 mmol/mol\], − 0.29% \[− 3.17 mmol/mol\], 9.5% \[80.3 mmol/mol\], − 0.69% \[− 7.54 mmol/mol\]).

Discussion {#Sec7}
==========

By investigating HbA~1c~ reduction across the continuum of baseline HbA~1c~ values, this exploratory post hoc analysis of data from the AWARD-5, AWARD-6 and AWARD-1 studies provides an in-depth evaluation of the primary results of these studies. The results of the current analysis indicate that incretin-based therapies effectively lowered HbA~1c~ irrespective of the HbA~1c~ value at baseline. Across the range of baseline HbA~1c~, patients treated with dulaglutide 1.5 mg achieved a similar mean reduction in HbA~1c~ to patients treated with liraglutide 1.8 mg (AWARD-6: Fig. [1](#Fig1){ref-type="fig"}b), and a greater HbA~1c~ mean reduction than patients treated with exenatide twice daily (AWARD-1; Fig. [1](#Fig1){ref-type="fig"}c) or sitagliptin (AWARD-5; Fig. [1](#Fig1){ref-type="fig"}a). These results are consistent with the primary analyses, which assumed the same effect of baseline HbA~1c~ for the whole ITT population \[[@CR13]--[@CR15]\].

The current analysis complements previous post hoc analyses \[[@CR24], [@CR25]\], which have categorised patients into distinct subgroups based on baseline HbA~1c~ cutoff values (e.g. \< 8.5% vs ≥ 8.5% \[69.4 mmol/mol\]). It has shown that in dulaglutide 1.5 mg and 0.75 mg treatment groups, HbA~1c~ was reduced in patients with baseline HbA~1c~ levels that ranged from 6.5% (47.5 mmol/mol) to 11.0% (96.7 mmol/mol) (Fig. [1](#Fig1){ref-type="fig"}). Once-daily sitagliptin and liraglutide 1.8 mg, and twice-daily exenatide, were also associated with reduced HbA~1c~ in patients with a range of baseline HbA~1c~ levels (sitagliptin, HbA~1c~ 7.0--9.5% \[53.0--80.3 mmol/mol\]; liraglutide 1.8 mg, HbA~1c~ 7.0--10.0% \[53.0--85.8 mmol/mol\]; exenatide, HbA~1c~ 6.5--11.0% \[47.5--96.7 mmol/mol\]; Fig. [1](#Fig1){ref-type="fig"}). These findings suggest that improvements in glycaemic control can be achieved with incretin-based therapies irrespective of the patient's HbA~1c~ value at the time therapy is initiated. Such improvements in glycaemic control will help to decrease the risk of microvascular complications across the broad spectrum of patients with T2DM \[[@CR28], [@CR29]\].

Moreover, in this post hoc analysis, there was a positive linear relationship between HbA~1c~ reduction at 26 weeks and baseline HbA~1c~ in patients treated with dulaglutide or liraglutide in AWARD-6, in patients treated with dulaglutide or exenatide twice-daily in AWARD-1, and in patients treated with dulaglutide or sitagliptin in AWARD-5 (Fig. [1](#Fig1){ref-type="fig"}). In dulaglutide 1.5 mg-treated patients with better glycaemic control at baseline (HbA~1c~ = 7% \[53.0 mmol/mol\]), the reductions were \< 1% (10.9 mmol/mol) in each of the AWARD-5, AWARD-6 and AWARD-1 studies at 26 weeks. In contrast, mean reductions ranged from 1.8% to 3.2% (19.8--35.0 mmol/mol\]) at 26 weeks in patients with poorer control at baseline (HbA~1c~ ≥ 9.5% \[80.3 mmol/mol\]) who received dulaglutide 1.5 mg. These outcomes are consistent with another post hoc analysis, which found that a higher baseline HbA~1c~ value reflecting poor glycaemic status was a major factor associated with a greater reduction in HbA~1c~ \[[@CR11]\]. A positive relationship between baseline HbA~1c~ and the magnitude of HbA~1c~ reduction has been reported in meta-analyses involving insulin analogues \[[@CR6]\] and ten categories of glucose-lowering therapies \[[@CR30]\], and in the nomogram developed by Esposito et al. \[[@CR8]\] to estimate the HbA~1c~ to estimate the HbA~1c~ response to different DPP-4 inhibitors.

The positive linear relationship that exists between incretin-associated HbA~1c~ reduction and baseline HbA~1c~ was evident with dulaglutide and liraglutide treatments in AWARD-6, with dulaglutide and exenatide twice-daily treatments in AWARD-1 and with dulaglutide and sitagliptin treatments in AWARD-5. There was no evidence of a significant treatment-by-baseline HbA~1c~ interaction in AWARD-6 or AWARD-1 (interaction *P*values, 0.605 and 0.443, respectively); however, a significant interaction was demonstrated in patients treated with dulaglutide versus sitagliptin in AWARD-5 (*P*value = 0.001), with a progressively greater HbA~1c~ reduction associated with dulaglutide 1.5 mg compared with sitagliptin as baseline HbA~1c~ increased. This significant interaction was confirmed at 52 weeks \[[@CR27]\]. The greater HbA~1c~ reduction in patients with higher baseline HbA~1c~ seen in those treated with dulaglutide 1.5 mg, compared with sitagliptin, could be related to the greater effect that GLP-1 RAs have on both fasting and postprandial glucose levels \[[@CR13], [@CR30]\].

This post hoc analysis indicates that consideration of a patient's baseline HbA~1c~ level is important because the glycaemic response varies among patients treated with different antihyperglycaemic agents, and these variances may be magnified at higher baseline HbA~1c~ levels (Fig. [1](#Fig1){ref-type="fig"}). In light of the relationship between the patient's baseline HbA~1c~ and their changes in HbA~1c~, this analysis highlights an opportunity for personalising therapy. Such personalisation of therapy is increasingly being seen as important in the optimal clinical management of patients with T2DM \[[@CR31]\], with the patient's age, their attitude to specific adverse effects of therapy, the presence of comorbid conditions and the duration of T2DM all being considered when a therapeutic strategy is being considered \[[@CR32]\].

This analysis has a number of limitations. These include the open-label design of AWARD-6 and AWARD-1 (which could have affected physicians' and patients' behaviour), the exploratory post hoc nature of the analysis and the absence of placebo-based correction for the absolute reductions in HbA~1c~ (only two of the three original AWARD trials included a placebo arm \[[@CR13]--[@CR15]\] and the data must be interpreted in the context of the absence of placebo data). In terms of the ANCOVA models used in the analysis, these did not include factors potentially associated with HbA~1c~ such as age and duration of diabetes \[[@CR33], [@CR34]\]. Although this may be regarded as a limitation, use of the simpler models allowed us to remain consistent with the original, pre-planned statistical analysis. Moreover, baseline HbA~1c~ is the major factor associated with change in HbA~1c~, irrespective of treatment \[[@CR10]\]. A post hoc analysis of studies involving dulaglutide showed that baseline HbA~1c~ accounted for 49% of relative influence, whereas the relative influence of other baseline characteristics such as age, fasting serum glucose or duration of diabetes was very small or of limited clinical significance \[[@CR11]\]. Consistency with the original analysis was also maintained by focussing solely on HbA~1c~ change from baseline; this outcome was the primary endpoint in the AWARD trials and therefore the most suitable for exploration in this analysis. It should be noted that, because this analysis presents data only for the baseline HbA~1c~ ranges specified by the inclusion criteria in each study, no conclusions can be drawn regarding the effect of incretin-based therapy in patients with HbA~1c~ levels outside these ranges.

Conclusion {#Sec8}
==========

The current post hoc analysis complements the primary analyses of the AWARD studies. Results indicate that patients treated with dulaglutide 1.5 and 0.75 mg experienced mean reductions in HbA~1c~ that were greater than those of patients treated with either exenatide twice daily or sitagliptin, and in patients treated with dulaglutide 1.5 mg, HbA~1c~ was reduced to the same extent as that seen in patients treated with liraglutide 1.8 mg, in all cases irrespective of the patient's baseline HbA~1c~ value. Since dulaglutide's ability to lower HbA~1c~ is durable and has been observed across patients with a broad range of HbA~1c~ levels, these results suggest that dulaglutide may be considered an appropriate option for a wide range of baseline HbA~1c~ levels, including those indicative of poor glycaemic control.
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